Bovine Viral Diarrhea (BVD)

Bovine Viral Diarrhea (BVD) is a highly significant viral disease of cattle caused by bovine viral diarrhea virus (BVDV), a member of the Pestivirus genus within the Flaviviridae family. This economically devastating pathogen affects cattle populations worldwide, causing a remarkably diverse range of clinical presentations from subclinical infection through severe acute disease to the invariably fatal mucosal disease. The ability of BVDV to cross the placenta and establish persistent infection in fetuses exposed during early gestation creates a unique epidemiological situation where apparently healthy animals serve as lifelong virus factories, continuously shedding virus and perpetuating infection within herds.

BVDV affects cattle of all ages, breeds, and production types, though the consequences of infection vary dramatically depending on immune status, pregnancy stage, and viral strain characteristics. Acute infections in immunocompetent cattle are often mild or subclinical, while the same virus can cause devastating reproductive losses, immunosuppression predisposing to secondary infections, or fatal mucosal disease in persistently infected animals. The virus exists as two distinct species, BVDV-1 and BVDV-2, each with numerous subtypes, and strains vary considerably in virulence from mild to highly pathogenic.

The economic impact of BVD on cattle operations extends far beyond direct mortality losses. Reproductive failure including early embryonic death, abortion, and congenital defects represents a major cost center in infected herds. Immunosuppression caused by BVDV increases susceptibility to respiratory disease complex, leading to higher treatment costs and production losses. Persistently infected animals that survive to productive age often perform poorly, creating ongoing economic drag. Studies consistently rank BVD among the most costly infectious diseases affecting the cattle industry, with estimates suggesting losses of billions of dollars annually worldwide.

Effective BVD control requires a comprehensive approach combining vaccination, biosecurity, and identification and elimination of persistently infected animals. Successful eradication programs have been implemented in several European countries, demonstrating that elimination is achievable with sustained commitment. For individual operations, working with a licensed veterinarian to develop customized prevention protocols based on herd risk factors and management constraints offers the best protection against this pervasive pathogen. Early identification of BVD problems through diagnostic testing enables prompt intervention before losses mount.

Bovine Viral Diarrhea Virus belongs to the Pestivirus genus, sharing taxonomic classification with classical swine fever virus and border disease virus of sheep. BVDV is an enveloped, single-stranded positive-sense RNA virus that demonstrates remarkable genetic diversity, with two recognized species and numerous subtypes identified through genetic sequencing. This diversity has practical implications for vaccine development and diagnostic testing, as cross-protection between subtypes may be incomplete. The virus can be further classified into cytopathic and non-cytopathic biotypes based on their effect on cell cultures, a distinction with critical importance for understanding mucosal disease pathogenesis.

The primary source of BVDV infection in cattle herds is persistently infected animals, which are created when pregnant cattle are exposed to non-cytopathic BVDV during the first trimester of gestation. Fetal infection before immune system development results in immunotolerance to the virus, producing calves that recognize BVDV as self and fail to mount an immune response. These persistently infected animals shed enormous quantities of virus in all bodily secretions throughout their lives, typically millions of viral particles per milliliter of nasal secretions compared to thousands during acute transient infections. A single PI animal can expose and infect an entire herd, making identification and removal of these animals the cornerstone of BVD control.

Environmental and management factors significantly influence BVDV transmission dynamics and disease impact. Direct contact between cattle provides the most efficient transmission route, with virus spread through nasal secretions, saliva, ocular discharge, urine, feces, milk, and reproductive fluids. Indirect transmission through contaminated equipment, vehicles, or personnel is possible but less efficient due to limited environmental survival of the enveloped virus. Commingling events including cattle shows, sales, and breeding exposures create opportunities for introduction to naive herds. Shared facilities, equipment, and fence-line contact with neighboring herds represent ongoing biosecurity concerns.

Risk factors for BVD problems include open herd status with regular additions of animals from outside sources, lack of vaccination programs, inadequate biosecurity practices, and failure to test and remove persistently infected animals. Young cattle experiencing their first pregnancy face the highest risk of producing PI calves if exposed during the critical early gestation window. Bulls, both natural service and artificial insemination, can serve as infection sources, with some PI bulls remaining fertile and capable of spreading virus through semen. Neighboring herds with unknown or positive BVD status increase risk through direct or indirect contact.

The pathophysiology of BVDV infection reflects the virus's tropism for rapidly dividing cells and its immunosuppressive properties. Acute infection involves viral replication in lymphoid tissue, bone marrow, and epithelial surfaces, causing lymphopenia and compromised immune function lasting several weeks. During pregnancy, viral invasion of the placenta and fetus may cause embryonic death, fetal resorption, abortion, stillbirth, congenital malformations, or persistent infection depending on gestational age and viral strain. In PI animals subsequently infected with a cytopathic BVDV strain homologous to their persisting non-cytopathic virus, mucosal disease develops through widespread epithelial necrosis, particularly in the digestive tract, producing the severe erosive lesions characteristic of this fatal syndrome.

Early warning signs of acute BVD infection are often subtle and easily overlooked in cattle populations. Initial symptoms may include mild fever with rectal temperatures reaching 104 to 106 degrees Fahrenheit, along with slight depression and reduced feed intake that may go unnoticed in group-fed cattle. Some animals develop transient nasal discharge or mild ocular discharge during the early phase of infection. Careful observation may reveal slightly decreased milk production in lactating cows or subtle changes in behavior. Many acute BVDV infections, however, remain completely subclinical, with animals seroconverting without displaying any recognizable clinical signs.

When clinical disease develops, symptoms vary considerably between species and age groups as well as between viral strains. Calves acutely infected with virulent BVDV strains may develop severe disease characterized by high fever, profound depression, and hemorrhagic syndrome with bleeding from multiple sites including nasal passages, injection sites, and the digestive tract. Adult cattle typically experience milder disease with fever, depression, oral erosions, and diarrhea, though highly pathogenic strains can cause severe illness in any age group. Respiratory involvement occurs commonly, with BVDV either causing primary respiratory disease or predisposing to bacterial pneumonia through immunosuppression.

Behavioral changes associated with BVD infection reflect both the direct effects of viral illness and the immunosuppression that increases susceptibility to secondary infections. Acutely infected animals often demonstrate reduced appetite, spending less time at feed bunks and showing decreased rumination activity. Lethargy and depression are common, with affected cattle standing with lowered heads and drooping ears. Social isolation from herdmates may be observed. In breeding herds, failure to conceive, return to estrus after breeding, or embryonic loss manifest as extended calving intervals and poor pregnancy rates.

Physical examination findings in BVD cases depend on the form and severity of disease. Acute infections may reveal fever, oral erosions affecting the dental pad, tongue, and gingiva, conjunctivitis with ocular discharge, and evidence of diarrhea. Lymph node enlargement reflects viral replication in lymphoid tissue. Pregnant animals may show no specific signs despite fetal infection that will result in abortion weeks later. Persistently infected animals often display poor growth rates, rough hair coats, and increased susceptibility to other diseases, though many appear clinically normal despite continuous virus shedding.

Symptom progression differs markedly between acute transient infections and mucosal disease. Acute infections typically resolve over one to three weeks as the immune system clears the virus, though immunosuppression may persist for several additional weeks. In contrast, mucosal disease in PI animals progresses relentlessly from initial fever and depression through severe bloody diarrhea, extensive erosive lesions throughout the digestive tract, and profound weakness to death within days to weeks. Chronic mucosal disease may persist for months with waxing and waning clinical signs before ultimate deterioration. No recovery from mucosal disease occurs.

Emergency symptoms requiring immediate veterinary attention include hemorrhagic syndrome with bleeding from nose, mouth, injection sites, or in feces, indicating possible infection with highly pathogenic BVDV-2 strains. Pregnant cattle aborting or showing other signs of reproductive failure warrant investigation for BVD involvement. Animals with severe erosive lesions in the mouth, profound dehydration from diarrhea, or rapid deterioration despite treatment require urgent evaluation. Any pattern suggesting disease spread through a group, particularly affecting pregnant animals or young calves, should prompt veterinary consultation and diagnostic testing.

Clinical examination provides initial assessment of suspected BVD cases, though the variable presentation makes definitive diagnosis based on clinical signs alone impossible. Veterinarians evaluate animals for characteristic findings including oral erosions, diarrhea, respiratory involvement, and evidence of hemorrhagic syndrome. History taking explores herd vaccination status, recent introductions, exposure opportunities, and patterns of reproductive failure or respiratory disease. The presence of poor-doing or stunted animals raises suspicion for persistently infected individuals. Group-level observations including disease patterns and production parameters often provide more diagnostic information than individual animal findings.

Laboratory diagnosis of BVDV employs multiple testing modalities to identify acute infection, persistent infection, and previous exposure. Virus isolation from blood, nasal swabs, or tissues demonstrates active infection and allows characterization of viral biotype and genotype. Polymerase chain reaction testing provides sensitive and rapid detection of viral RNA in various sample types. Antigen-capture ELISA performed on blood samples or ear notch samples offers a practical screening method for identifying PI animals. Bulk tank milk testing in dairy herds can indicate the presence of actively shedding animals. Serology to detect BVDV antibodies identifies previous exposure but cannot distinguish vaccination from natural infection.

Identification of persistently infected animals represents the most critical diagnostic goal for BVD control programs. PI animals lack BVDV antibodies because they are immunotolerant to the virus, while demonstrating high levels of viral antigen or RNA. Testing strategies typically involve initial screening of entire groups using ear notch immunohistochemistry, antigen-capture ELISA, or pooled PCR testing. Positive or suspect animals require confirmatory testing, with repeat testing after at least three weeks confirming persistent rather than acute infection. Testing all newborn calves before commingling with the herd identifies PIs before they spread virus to pregnant animals.

Herd-level diagnostics help characterize BVD status and guide control program development. Antibody prevalence testing across different age groups reveals patterns of virus circulation and identifies groups likely to contain PI animals. Sequencing of viral isolates can link cases within and between herds for epidemiological investigation. Bulk tank milk antibody testing provides ongoing monitoring in dairy herds. Regular testing of additions before entry detects infected animals before they introduce virus. Reproductive failure investigations including testing of aborted fetuses and evaluation of breeding records often reveal previously unrecognized BVD problems.

No specific antiviral treatment exists for bovine viral diarrhea virus infection, making supportive care the foundation of therapeutic management. Animals with acute BVD showing clinical signs benefit from anti-inflammatory therapy to reduce fever and improve comfort. Non-steroidal anti-inflammatory drugs such as flunixin meglumine or meloxicam provide antipyretic and anti-inflammatory effects while being approved for use in cattle with appropriate withdrawal time observance. Fluid therapy addresses dehydration in animals with diarrhea, administered intravenously for severe cases or orally for milder dehydration. Nutritional support including palatable feeds and protected areas for eating encourages continued intake during illness.

Secondary bacterial infections commonly complicate BVD due to viral immunosuppression, requiring antimicrobial intervention. Respiratory disease following BVDV infection often involves Mannheimia haemolytica, Pasteurella multocida, or Histophilus somni, warranting antimicrobial selection effective against these pathogens. Gastrointestinal complications may benefit from antimicrobial therapy targeting likely enteric pathogens. Selection of specific antimicrobials should follow veterinary guidance based on likely pathogens, regional resistance patterns, and withdrawal time requirements for food-producing animals. Treatment duration typically continues until clinical improvement is established and maintained.

Persistently infected animals present a unique treatment dilemma because their infection is permanent and they serve as continuous sources of virus for other cattle. Treatment of PI animals for secondary diseases may provide temporary improvement but does not address the underlying viral shedding. From a herd health perspective, maintaining PI animals perpetuates BVD circulation regardless of their individual clinical status. The only effective management of PI animals is removal from the herd through culling, with appropriate disposal or marketing to terminal destinations where they will not contact breeding cattle.

Mucosal disease carries a hopeless prognosis, and treatment beyond palliative care is not warranted. Affected animals invariably die regardless of therapeutic intervention. Humane euthanasia should be considered promptly once mucosal disease is diagnosed or strongly suspected, as continued supportive care only prolongs suffering without possibility of recovery. Animals with mucosal disease should not enter the food chain if showing systemic illness, and carcass disposal should prevent potential environmental contamination.

Herd-level treatment considerations extend beyond individual sick animals to address the underlying BVD problem. Metaphylactic antimicrobial treatment of groups at high risk for secondary bacterial disease following BVDV exposure may reduce morbidity and mortality. Enhanced monitoring during and after suspected BVD exposure enables earlier treatment of developing cases. Temporary segregation of obviously ill animals limits direct transmission while allowing continued observation. Pregnant animals exposed to BVDV require monitoring for reproductive consequences even if they show no clinical illness.

Economic factors heavily influence BVD treatment decisions given the lack of specific therapy and the herd-level implications of the disease. Individual animal treatment costs must be weighed against the value of the animal and probability of productive return. Investment in identifying and eliminating PI animals typically provides better return than continued treatment of BVD-related problems in infected herds. Veterinary consultation helps producers navigate these decisions, balancing individual animal welfare, herd health, and economic sustainability.

Recovery from acute transient BVD infection typically occurs over one to three weeks in immunocompetent cattle without concurrent disease complications. The immune system mounts a response that clears the virus from blood and tissues, with antibodies detectable within two to three weeks of infection and providing solid immunity against reinfection with the same viral strain. Clinical signs including fever, depression, and diarrhea resolve as viral replication decreases. However, the immunosuppressive effects of BVDV may persist for several weeks beyond clinical recovery, leaving animals vulnerable to secondary infections during this period.

Post-treatment care and monitoring of BVD-affected animals focuses on supporting complete recovery and watching for complications. Recovering animals benefit from reduced stress, including appropriate housing, readily available feed and water, and minimal handling. Gradual return to normal management routines prevents setbacks from excessive demands during recovery. Monitoring for respiratory disease or other secondary infections should continue for several weeks given prolonged immunosuppression. Weight monitoring identifies animals failing to regain lost condition or achieve expected growth despite apparent clinical recovery.

Prognosis for acute BVD depends heavily on viral strain characteristics, animal immune status, and development of complications. Infections with mild strains in healthy adults carry excellent prognosis, with many animals experiencing subclinical infection requiring no treatment. Highly pathogenic BVDV-2 strains causing hemorrhagic syndrome carry guarded to poor prognosis even with intensive treatment. Young animals with immature immune systems and animals with concurrent infections face higher mortality risk. Development of severe secondary bacterial pneumonia worsens prognosis significantly.

Return to production following BVD recovery requires attention to both the recovered individual and herd-level implications. Animals recovering from clinical BVD typically return to normal productivity once fully recovered, though the time required varies with disease severity. Dairy cows may show reduced milk production for the remainder of a lactation affected by illness. Breeding animals should be retested to confirm clearance of virus before exposure to pregnant cattle. Animals that seroconvert following natural infection demonstrate immunity but their presence indicates virus circulation requiring investigation for PI animals as the source.

Vaccination against BVDV forms a critical component of comprehensive BVD prevention programs. Both modified-live and killed vaccines are commercially available, with most products protecting against both BVDV-1 and BVDV-2 species. Modified-live vaccines generally provide stronger immune response and may be administered intranasally for rapid mucosal immunity. Killed vaccines offer safety advantages in pregnant animals, as modified-live vaccines carry theoretical risk of fetal infection. Vaccination programs typically begin in calves after maternal antibody decline, with boosters establishing solid immunity before breeding age. Annual revaccination maintains protection, with breeding females often vaccinated before each breeding season.

Biosecurity measures provide essential protection against BVD introduction to naive herds. Closed herd management eliminating all outside cattle introductions offers the highest level of protection but is impractical for many operations. When cattle must be purchased, sourcing from herds with documented BVD-free status or active control programs reduces risk. All incoming animals should be tested for PI status and quarantined until negative results are confirmed. Physical separation from resident cattle during quarantine prevents nose-to-nose contact that could transmit virus. Artificial insemination using semen from tested-negative bulls eliminates a potential infection route.

Identification and elimination of persistently infected animals is the single most important BVD control measure. PI animals serve as the primary reservoir maintaining BVDV in cattle populations, and their removal breaks the infection cycle. Whole-herd testing identifies existing PI animals for removal. Testing all calves at birth or before commingling with the breeding herd prevents new PIs from reaching productive age. Retesting animals with questionable initial results after three or more weeks distinguishes persistent from acute infection. Pregnant animals that test negative but were exposed to BVDV may be carrying PI fetuses, requiring offspring testing at birth.

Management practices supporting BVD prevention reduce exposure opportunities and optimize immune function. Segregation of pregnant animals, particularly during the first trimester, from potential virus sources protects against PI calf production. Avoiding commingling of cattle from different sources reduces transmission opportunities. Stress reduction through appropriate handling, nutrition, and environmental management supports immune competence. Complete colostrum management ensures passive antibody transfer to newborn calves. Maintaining closed herds or herds from tested sources for fence-line contacts prevents exposure from neighboring cattle.

Eradication programs combining testing, elimination of PI animals, vaccination, and biosecurity have successfully eliminated BVD from cattle populations in several European countries. These programs typically begin with identifying and removing all PI animals, followed by ongoing testing of additions and newborn calves to detect any new infections. Vaccination may continue during eradication to provide additional protection but can be discontinued once virus-free status is achieved and maintained. Success requires sustained commitment, consistent implementation, and coordination across neighboring herds and regions.

Daily management and monitoring for BVD-endemic herds emphasizes early detection of clinical disease and maintenance of prevention protocols. Regular observation of all cattle groups identifies animals showing depression, fever, diarrhea, or other signs suggesting acute BVD or secondary disease. Monitoring reproductive performance including conception rates, return to estrus patterns, and calving intervals reveals problems potentially related to BVD. Tracking respiratory disease incidence helps assess the immunosuppressive impact of circulating virus. Production monitoring including daily milk weights, average daily gains, and feed efficiency provides objective measures of subclinical BVD effects.

Housing and environmental management considerations for BVD control focus on limiting transmission opportunities between infected and susceptible animals. Physical barriers preventing nose-to-nose contact between groups reduce direct transmission. Separate housing for pregnant animals, particularly those in the first trimester, provides protection during the critical period for PI calf production. Calving facilities should allow for separate housing of newborns until PI testing is complete. Adequate ventilation reduces aerosol transmission in enclosed facilities. Cleaning and disinfection between animal groups limits environmental persistence of virus.

Herd health programs addressing BVD should be developed collaboratively with a licensed veterinarian familiar with the operation's specific circumstances. Comprehensive programs include vaccination protocols tailored to the herd's BVD status and risk level. Testing strategies for identifying PI animals should be defined, including timing of calf testing and protocols for purchased animal evaluation. Treatment protocols for BVD-associated disease conditions ensure consistent management when clinical cases occur. Regular program review incorporates new diagnostic information and evaluates progress toward control or eradication goals.

Record keeping systems supporting BVD management track vaccination status, test results, and health events for individual animals and groups. Individual animal records should document vaccination dates and products, PI test results with dates, and any BVD-related health events. Group records track disease incidence, reproductive performance, and production parameters that may reflect subclinical BVD impact. Purchase records including source herd information and testing documentation support biosecurity programs. These records enable analysis of program effectiveness and identification of problems requiring intervention.

Economic analysis of BVD management options helps producers make informed decisions about control intensity. Cost-benefit evaluation should compare the expenses of testing, vaccination, and biosecurity measures against losses from reproductive failure, treatment costs, mortality, and production impacts associated with uncontrolled BVD. The return on investment for PI testing programs is typically highly favorable given the concentrated viral shedding from these animals. Vaccination costs are modest compared to potential losses from acute disease outbreaks or reproductive failure. Producers should work with veterinarians and extension specialists to develop realistic economic projections for their specific situations.

All cattle breeds are susceptible to BVDV infection without meaningful breed-related resistance. Holstein, Jersey, and other dairy breeds experience BVD across all production regions where the virus is present. Beef breeds including Angus, Hereford, Simmental, Charolais, and their crosses demonstrate equal susceptibility when exposed. No documented genetic resistance to BVDV exists within any cattle breed, and breeding programs have not identified or selected for resistance traits. The universal susceptibility of cattle to this virus emphasizes the importance of management-based control strategies including vaccination, biosecurity, and PI animal identification.

Production system differences create varying BVD risk profiles independent of breed. Dairy operations with frequent cattle purchases, artificial insemination, and intensive calf-rearing systems face unique challenges including multiple introduction routes and concentrated young animal populations. Beef cow-calf operations may maintain more closed herds but face risks from bull turnover, fence-line contact with neighbors, and commingling at sales and shows. Feedlots receiving cattle from multiple sources concentrate animals with varying BVD status and viral strain exposure histories. Seedstock operations with high-value genetics often implement more intensive control programs to protect breeding stock investments.

Genetic factors influencing BVD susceptibility remain poorly characterized, though research suggests individual variation in immune response to BVDV infection. Some animals may develop stronger or longer-lasting immunity following vaccination or natural exposure, though the genetic basis for this variation is unclear. Selection for general immune competence or disease resistance may indirectly improve BVD outcomes but no specific genetic markers are available for breeding decisions. The focus of BVD control should remain on management factors including vaccination, biosecurity, and PI elimination rather than genetic selection approaches that lack proven effectiveness.

Bovine respiratory disease complex represents the most common clinical context where BVD plays a significant role. BVDV immunosuppression increases susceptibility to respiratory pathogens including Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis. Concurrent infection with other viral respiratory pathogens such as infectious bovine rhinotracheitis, parainfluenza-3, and bovine respiratory syncytial virus further compounds respiratory disease severity. Control of BVD contributes significantly to overall respiratory disease reduction in cattle populations.

Other Pestivirus infections demonstrate relationships to BVD through shared taxonomic classification and potential for cross-species transmission. Border disease virus of sheep can occasionally infect cattle, particularly those sharing facilities or pastures with infected sheep populations. While cross-protection between related pestiviruses may occur, vaccines designed for one species may not provide complete protection against heterologous viruses. Diagnostic testing may show cross-reactivity between pestiviruses, requiring careful interpretation in mixed-species operations.

Reproductive failure conditions commonly associated with BVD include early embryonic death, abortion, congenital malformations, and the birth of weak or PI calves. Differential diagnosis for bovine reproductive failure includes numerous other infectious causes such as infectious bovine rhinotracheitis, leptospirosis, neosporosis, trichomoniasis, and campylobacteriosis. Non-infectious causes including nutritional deficiencies, toxic exposures, and genetic factors also require consideration. Comprehensive reproductive failure investigation should include BVD testing regardless of vaccination status, as vaccine breaks can occur and PI animals may circulate in apparently protected herds.